Modulator treatment for people with cystic fibrosis: moving in the right direction

J. Stuart Elborn

Source: Eur Respir Rev, 29 (155) 200051; 10.1183/16000617.0051-2020
Journal Issue: March
Disease area: Paediatric lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Stuart Elborn. Modulator treatment for people with cystic fibrosis: moving in the right direction. Eur Respir Rev, 29 (155) 200051; 10.1183/16000617.0051-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Tezacaftor-ivacaftor for the treatment of cystic fibrosis: what’s next?
Source: International Congress 2018 – Therapeutic breakthroughs Year in Review
Year: 2018


Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
Source: Eur Respir J 2015; 45: 1208-1210
Year: 2015


Can step be a maximal test in children with cystic fibrosis?
Source: Annual Congress 2009 - Paediatric lung function, imaging and methodology in health and disease
Year: 2009


Does this patient have cystic fibrosis? 
Source: International Congress 2017 – GR6 Paediatric Ground Round: an interactive session
Year: 2017


Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward
Source: Eur Respir J 2013; 42: 1446-1448
Year: 2013


Intervention trials and ventilation distribution in mild cystic fibrosis lung disease: will it all come out in the wash?
Source: Eur Respir J 2011; 37: 757-759
Year: 2011


Treatment of right heart failure on pulmonary arterial hypertension: is going left a step in the right direction?
Source: Eur Respir Rev 2009; 19: 4-6
Year: 2010


Lung inflammation in cystic fibrosis: an overlooked therapeutic target?
Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age
Year: 2020


The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
Source: Breathe, 17 (1) ; 10.1183/20734735.0013-2021
Year: 2021



Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end
Source: Eur Respir J, 52 (6) 1802111; 10.1183/13993003.02111-2018
Year: 2018



High frequency chest wall oscillation (HFCWO) in the treatment of acute pulmonary exacerbation in adult cystic fibrosis (CF) patients
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013


Cystic fibrosis patients: do they profit from altitiude residence?
Source: Annual Congress 2006 - Man at altitude: benefits and risks of pre-existing respiratory impairment due to various diseases
Year: 2006


The therapy of idiopathic pulmonary fibrosis: what is next?
Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019
Year: 2019



Monitoring early lung disease in cystic fibrosis: where are we now?
Source: Breathe 2014; 10: 34-47
Year: 2014



A new paradigm for the management of children with cystic fibrosis at home: experiences from a Dutch cystic fibrosis clinic
Source: Virtual Congress 2021 – New technologies for the management of children with respiratory diseases
Year: 2021


Evaluation of a novel chest wall motion analysis system in cystic fibrosis and healthy volunteers
Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system
Year: 2015


Idiopathic pulmonary fibrosis: time for greater expectations?
Source: Eur Respir J, 52 (2) 1801312; 10.1183/13993003.01312-2018
Year: 2018



Patient centred research: a model for involving cystic fibrosis (CF) patients in research planning
Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis
Year: 2019